Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib in Previously Treated NSCLC With KRAS G12C Mutation
NCT05853575Phase 2Active, not recruiting
- Sponsor
- Mirati Therapeutics
- Start
- Feb 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, randomised trial of adagrasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Mirati Therapeutics. Primary endpoint: Objective Response Rate at 30 months. Started Feb 2024; status: active, not recruiting.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05853575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05853575.